Application of the CRISPR/Cas۹-based gene editing technique in basicresearch, diagnosis, and therapy of blood cancer
- سال انتشار: 1403
- محل انتشار: سومین همایش بین المللی زیست شناسی و علوم آزمایشگاهی
- کد COI اختصاصی: ZISTCONF03_053
- زبان مقاله: انگلیسی
- تعداد مشاهده: 57
نویسندگان
Department of Biology, Semnan University, Semnan, Iran,
Cellular and Molecular Research Center, Qom University of Medical Sciences, QomIran,
چکیده
IntroductionCRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) was first discovered in Escherichia coli.While many CRISPR–Cas systems exist, only a few have been used as research tools. CRISPR-Cas۹, known forits precision and versatility, has revolutionized genome editing due to its cost-effectiveness and ease of use.Hematological malignancies, which arise in blood-forming and lymphoid tissues, rank as the fifth most commoncancer globally. The CRISPR/Cas۹ gene editing technique has become a powerful tool in biomedical research,with transformative potential in the study and treatment of blood cancers.MethodIn this review, electronic databases such as PubMed, Scopus, ScienceDirect, and Google Scholar were searched.Studies exploring the application of CRISPR/Cas۹ in basic research, diagnosis, and therapy of blood cancers wereincluded.DiscussionThe reviewed studies demonstrate how CRISPR/Cas۹ aids in modeling genetic mutations that underlie bloodcancers, offering insights into disease mechanisms and potential therapeutic targets. Additionally, CRISPR/Cas۹enhances the accuracy of blood cancer diagnoses and enables personalized medicine by identifying specificgenetic mutations. Therapeutically, CRISPR/Cas۹ can be used to target gene editing for the knockout orcorrection of disease-causing mutations and develop innovative therapies like CAR T-cell therapy. However, off-target changes in the genome are a significant concern. To increase editing precision, high-fidelity Cas variantssuch as SpCas۹-HF۱, HiFiCas۹, and Sniper۲L have been developed, along with laboratory-evolved Cas variantscompatible with PAM sequences.ConclusionThis review suggests that the CRISPR/Cas۹ gene editing technique is a crucial tool for investigating and treatingblood cancers. Despite challenges and limitations, CRISPR/Cas۹ holds promise for revolutionizing blood cancerresearch and treatment paradigms. However, these technologies are relatively new and more fundamental,necessitating further research and clinical trials to establish their safety and effectiveness.کلیدواژه ها
CRISPR/Cas۹, gene editing, blood cancersمقالات مرتبط جدید
- استفاده از جلبک ها در تصفیه پساب فاضلاب: بررسی روش ها، چالش ها و کاربردها
- Isolation and Identification of Effective Probiotics on Staphylococcusepidermidis Strains Isolated from Urine Sample
- اولین گزارش از انگل های خونی میکروسکوپی در وزغ تالشی(Bufo eichwaldi)در شمال ایران
- "Computational Analysis of Isoliquiritigenin as a Potential MAPK۳ Inhibitorin Rectal Cancer: Integrating Transcriptomics, Molecular Docking, andDynamics Simulations"
- “Targeting MMP۷ in Rectal Cancer: Exploring the Therapeutic Potential ofBerberine through Bioinformatics and Molecular Docking Approaches”
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.